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Abstract:
Objective: Deficiency of
immunoglobulin (Ig) may be responsible for
recurrent infections in chronic obstructive
pulmonary disease (COPD). Our aim was to
investigate the level of IgG subclass (IgGsc) in
the epithelial lining fluid (ELF) and to try to
find a possible relation between these levels
and serum or bronchoalveolar lavage (BAL)
IgGsc levels in COPD patients with recurrent
acute exacerbation.

1

Departments of
Chest Diseases and
2
Tuberculosis, Biochemistry,
Faculty of
Medicine, Ankara University, Ankara TURKEY

Methods: Twenty-four clinically stable nonsmoking COPD patients who had developed
recurrent exacerbations three or four times a
year and 17 individuals without COPD were
enrolled as the experimental and control
groups (Group I and II) respectively. The BAL
procedure was performed on the groups by
bronchofiberoscope. In order to calculate ELF
Ig values, IgGsc and urea levels in sera and
BAL fluids were measured.
Results: Total Ig levels did not differ between
the groups. All serum IgGscs except IgG1

Introduction
Deficiency of immunoglobulin(s) (Ig) in serum is characterized by recurrent infections such as bronchitis,
sinusitis and otitis media, usually caused by S. pneumoniae, H. influenzae and S. aureus. For these patients, deficiency of immunoglobulin A (IgA) may co-exist (1).
Defects in the immune system have recently been reported in patients with chronic obstructive pulmonary disease
(COPD). The most frequently detected defect is the
humoral immune defect. The deficiency of IgG subclass
(IgGsc) has been implicated for the recurrent infections in
patients with COPD (2,3).
For acutely exacerbated COPD patients, the number of
bacteria in the sputum is higher than during the stable
period, and/or neutrophil leukocytes are two-fold elevated. In contrast to other subjects with infection, these
patients do not necessarily have fever, chills, leucocytosis

increased in Group I versus the control group
[mean
values
(mg/L)]:
IgG2=3734,
IgG3=1119, IgG4=405; p<0.05). However,
in the ELF, mean IgG1 and IgG2 levels
significantly decreased (367.3mg/L and
201.7mg/L respectively; p<0.05). BAL
IgGsc/urea ratios significantly were correlated
with ELF IgGsc levels (p<0.0001, r>0.8)
suggesting that only BAL urea and IgGsc
measurements were sufficient when
comparing the groups.
Conclusion: Immunologic response may be
impaired in COPD due to the deficiency of
IgGsc. The decrease in IgG1 and IgG2 in ELF,
which impairs the local pulmonary response,
may be responsible for the recurrent
exacerbations in patients with COPD.
Key Words: Bronchoalveolar lavage (BAL),
epithelial lining fluid (ELF), chronic
obstructive pulmonary disease (COPD),
immunoglobulin deficiency, immunoglobulin
subclass deficiency.

or a high erythrocyte sedimentation rate. Before starting
the treatment for an acute exacerbation, the causative
infective agent should be determined. Some of the most
common causative agents are S. pneumoniae, H. influenzae, Morexella catarrhalis and viruses (4).
The major soluble Igs in bronchoalveolar lavage (BAL)
fluid are IgGsc and IgA. A small amount of IgM is also
found. Complements acting in classical and alternate
pathways can also be shown in BAL fluid (5-9).
IgG constitutes of 70-75% of serum Igs. It has four
subclasses, namely IgG1, IgG2, IgG3 and IgG4 (10-12).
IgG1 and IgG3 are complement fixating antibodies,
whereas IgG2 and IgG4 can bind to a complement weakly. IgG1, IgG2 and IgG4 are responsible for the immune
reaction against the protein antigens. IgG4 is a blocking
antibody like IgE, and it can initiate type I and type III
allergic responses (13-15).
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IgG Subclass Levels in ELF in COPD

Since IgG1 constitutes the major part of total IgG, its
deficiency gives rise to serious clinical problems such as
sepsis or necrotizing enterocolitis in infancy or recurrent
sinopulmonary infections in early childhood. In the deficiency of IgG2, sinopulmonary infections are frequently
seen and these patients cannot cope with bacteria which
have a polysaccharide cell wall. Isolated or combined deficiency of IgG3 is rarely seen and may be familial. IgG4
may play a role in asthma and is too low to be detected
in serum or in BAL, unless commercial kits for ultralow
levels are used (10,11,13,16,17).
Our aim was to investigate the levels of Igs and IgGscs
in epithelial lining fluid (ELF) of COPD patients with
recurrent lower respiratory tract infections.

Materials and Methods
Study subjects
Forty-one patients (33M, 8F) were enrolled in the
study. The mean age was 50.2±17.2 years, ranging
from 17 to 73.
Group I: Twenty-four patients (20 males, 4 females)
with COPD, who were clinically stable for at least 6
weeks, constituted Group I. The diagnosis of COPD was
established as defined by the American Thoracic Society
(ATS) (4). The mean age was 60.1±10.4 years, ranging
from 30 to 73. They were not on systemic steroids and
they were ex-smokers for at least one year with a history of about 49 pack-years of smoking. All patients had a
history of acute exacerbation at least three or four times
a year. The patients with acute exacerbation were given
treatment until they were in stable clinical condition lasting at least 6 weeks. Patients who had bronchiectasis,
sinusitis, tonsillitis or any other chronic infective diseases
or malignancy were excluded.
Group II: Seventeen control patients (13 males, 4
females) with a history of tobacco consumption of about
30 pack-years constituted the control group. The mean
age was 56.1±14.7 years, ranging from 17 to 61. They
underwent Fiberoptic bronchoscopy (FOB) for indications
as follows: nonproductive cough (n:7), hemoptysis
workup (n: 3), suspected tuberculosis activity (n: 2), suspected hilar or pulmonary mass (n: 2 in each) and suspected sarcoidosis (n: 1). Although FOB indications suggest some disease, in Group II patients, followed up for
eight or twelve months, no malignant disease or disease
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suspected before FOB was observed. Furthermore, they
had not used any drug or smoked for at least one year
and had no symptoms of COPD.
Study design: Prospective study performed in a university hospital. The independent variable was existence
of COPD with frequent acute exacerbations and the
dependent variable was deficiency of immunoglobulins in
ELF and related samples.
The study was approved by the Ankara University
Hospital Ethics Committee and written informed consent
was obtained from each subject before their participation
in the study.
FOB: The tracheobronchial tree was observed through
a bronchofiberoscope (Olympus BF, IT20D). The
bronchial mucosa was visually evaluated by two bronchoscopists in the same session and the chronic mucosal
changes due to inflammation were scored by using the
criteria of chronic bronchitis index (CBI) (18)(Table 1).
Special attention was paid to the relation between CBI
and clinical symptoms. The bronchoscopists were
unaware of the study group and they were also unaware
of the score of each other.
BAL: The bronchofiberoscope was wedged in the
peripheral bronchus of the middle lobe or lingula and a
catheter was pushed out of the distal end. Then 100 ml
of 0.9% saline solution was instilled in 5 aliquots and
retrieved immediately with “zero dwell time”. As BAL
measurements are important for ELF calculations, “dwell
time” was assumed to be less than 20 seconds. Increased
dwell time is known to result in increased concentrations
of urea and protein level in the recovered BAL. Immediate aspiration of instilled saline allowed the least possible
amount of diffussion of molecules from sources. Using a
time of 20 seconds, this calculation suggested that a minimum of 80% of urea recovered in BAL fluid was derived
in situ in ELF and a maximum of 20% was derived from
diffusion. By this procedure approximately 50±2% of the
100 ml of instilled saline was recovered in both groups.
The BAL was filtered through 3 layers of gauze and centrifuged at 500 g for 10 minutes. The supernatant was
stored at –70°C for Ig analysis and at –20°C for urea
analysis (19,20).
Immunoglobulin analysis: Serum IgG, IgA, IgM and
IgE levels were measured with nephelometry in our laboratory of immunology. Normal range of values were,
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Table 1.

Endoscopic scores of airways inflammation (CBI)

Score

Erythema

Oedema

Secretions

Friability

0

None

None

None

None

1

Light red

Blunting of airway bifurcations

Strands of clear mucus

Punctate submucosal haemor
rhage with scope trauma

2

Red

Loss of normal airway indentations

Globules of mucus

Linear submucosal haemor
rhage with scope trauma

3

Beefy red

Airway occluded

Airway occluded

Frank bleeding with scope trauma

IgG: 6.5-16 g/L; IgA: 0.45-3.5 g/L; IgM: 0.5-3.2 g/L;
IgE: 1.0-100 kU/ml.
Quantitative IgG subclass measurements in sera (sIgGsc) were performed using a radial immunodiffusion
(RID) kit (Single Dilution RID, BIND A RID-The Binding
Site Limited-UK). The control serum in the kit was used
for quality control purposes. This serum was treated
exactly like a test sample, giving a diameter in keeping
with the concentration stated on the bottle, confidence
limits ±0.3mm. For example, if the IgG1 concentration
quoted on the serum bottle was 6100 mg/L, this was
equivalent to a ring diameter of 6.4mm (from RID reference table). The control serum therefore gave a ring
diameter in the range 6.1-6.7mm and normal ranges of
this kit were (g/L),
IgG1: 3.15-8.42; IgG2: 1.39-5.54; IgG3: 0.04-1.19;
IgG4: 0.01-0.9 (21).
Levels of IgGsc in the BAL (B-IgGsc) of the subjects
were measured with commercial kits (Specific Instructions IgG Subclasses Ultra Low Level- NANORID-The Binding Site Limited-UK). After the required diffusion time,
ring diameters were measured to the nearest 0.1mm
with a jewellers’ eyepiece in a double blind manner for
serum and B-IgGsc measurements. For BAL fluid samples
suspected of containing low concentrations of the specific protein, a “double fill” of the well was performed,
along with the 1:1 diluted calibrator of the respective low
value, and the obtained results were corrected (21-23).
IgGsc content of ELF: As BAL is a diluted material
representative of the lower respiratory tract, ELF was
also worked out. Because of its ready diffusion through
the body compartments including the lung, urea concentrations in sera and lavage fluids were used to quantify
the IgGsc concentrations of ELF. The concentrations of

urea in serum and in situ ELF are assumed to be identical. The level of IgGsc in ELF (E-IgGsc) was worked out
using the following formulas (19,24-27):

(1) ELF volume = BAL[urea] x BAL volume
Serum [urea]
(2) E-IgGsc = BAL volume x B-IgGsc
ELF volume
(3) E-IgGsc = B-IgGsc x Serum [urea]
BAL [urea]

To measure urea concentration in BAL fluid, a commercially available serum urea measuring kit (Sigma Diagnostics, BUN, Endpoint, UV-66) was used with slight
modifications. The BUN concentration is measured by
coupled enzyme reactions involving urease and glutamate
dehydrogenase (coefficient of variation: 0.6-2.4%). In
contrast to the 3.0 ml recommended by the supplier, a
2.5 ml reaction mixture was used and a 0.5 ml BAL fluid
sample (rather than the 0.01 ml in the instructions) was
analyzed in combination with saline and lavage fluid
blanks to correct for dilution reactant and optical
absorbance of the sample at 340 nm respectively (20). In
a recent study by Wichert et al., urea concentrations were
less variable than albumin concentrations in patients from
different disease groups, and it was concluded that urea
might be the preferred denominator for BAL studies (28).
Pulmonary Function Test (PFT): Spirometric tests
were performed using Vitalograph alpha spirometer. PFT
parameters were expressed as percentages of the predicted values.
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Arterial blood gas analysis: The arterial blood gases
were analyzed by Radiometer ABL 330. PaO2 and PaCO2
were expressed in mmHg, and oxygen saturation in percentages.

IgM, IgA) was not different between the groups.
Although IgE levels of eight subjects (38%) of Group I
and three (33%) of Group II were high, the groups did
not significantly differ (p>0.1) (Table 3).

Statistics: Statistical evaluation was done with a PC
using SPSS. The results were expressed as mean ± standard deviation (SD). The differences between the groups
were evaluated by Student’s t test and Mann-Whitney U
test. The correlation of B-IgGsc and E-IgGsc was assessed
by the Spearman correlation analysis test. Any p value less
than 0.05 was considered significant.

In Group I, mean levels of IgG2, IgG3 and IgG4 in sera
were found to be significantly high (p<0.05). However,
IgG1 and IgG2 in ELF (or BAL) were significantly lower
than those in Group II (p<0.05) (Table 4).

Results
Both groups had smoked almost equally but the spirometric results and arterial blood gas analysis of Group I
were significantly deteriorated as expected and the visual
endoscopic scores for the inflammation of the bronchial
mucosa (CBI) were significantly elevated when compared
to those of Group II (p<0.01)(Table 2).
Both groups were comparable in terms of total Ig
main class levels in the sera. We did not find IgGsc or
main class deficiency in sera between the groups. According to normal ranges, 66% of Group I patients had higher than normal values of at least one IgGsc. When mean
levels of Igs were compared, the main class of Igs (IgG,

Group I (COPD)
(mean±SD)
Age (years)
Smoking history (pack-years)
FVC (% of predicted)
FEV1 (% of predicted)
FEV1/FVC (%)
MMF (% of predicted)
PaO2 (mmHg)
PaCO2 (mmHg)
CBI

Table 3.

Discussion
Groups I and II were comparable in terms of smoking
history. However, Group I had lower spirometric PaO2
and O2 saturation values, and higher PaCO2 and CBI values when compared to Group II. These findings were all
expected because the control subjects had normal lungs in
clinical and radiological aspects although they had smoked
as heavily as Group I had.
In Group I, mean s-IgGsc (IgG2, IgG3, IgG4) levels
were significantly elevated. Sixteen subjects of Group I

Group II (CONTROL)
(mean±SD)
56.1±14.9
34 ±23
83.9±29.9
92.6±19.3
75.9±20.9
72.2±39.2
83.7±9
32.2±3.6
6.7±3.6

Table 2.

Features of the subjects

p
p>0.05
p>0.05
p>0.05
p=0.003
p=0.004
p=0.006
p=0.0001
p=0.005
p=0.003

Comparison of serum Ig main classes in both groups. Serum Igs were not statistically different between the groups.

Group I (COPD)
Group II (CONTROL)
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60.2±10.4
49.2±30
70.7±27.9
62.9±31.2
64±19.1
37.1±36.7
64.9±13.3
39.2±6.9
18.5±9.9

In order to standardize the B-IgGsc results, we
planned to express them as ratios of B-IgGsc to urea
(Table 4). As B-IgGsc/urea ratios were strongly correlated with E-IgGsc values (r>0.8, p<0.001) (Figure 1), we
expressed the value of B-IgSC as ELF Igs by applying the
formulas mentioned above.

IgG (g/L)

IgM (g/L)

IgA (g/L)

IgE (kU/m/L)

18.24±6.10
16.52±3.15

2.71±3.57
2.80±2.08

3.22±2.33
2.30±0.33

327±605.8
138.20±239
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Table 4.

Comparison of serum and ELF IgGsc levels in COPD and control subjects.

Immunoglobulins (mg/L)
(mean±SD)

Location

Group I (COPD)
(n=24)

Group II (CONTROL)
(n=17)

p value

IgG1

Serum
BAL IgG1/urea
ELF

6714.17± 2373.14
2.65±3.67
367.38± 325.71

6625.88± 1809.46
6.58±7.00
1019.8±1264.15

p>0.05
p=0.01
p=0.01

IgG2

Serum
BAL IgG2/urea
ELF

3734.17± 1356.30
1.25±1.94
201.76±245.35

2954.12± 1106. 52
2.13±1.89
360.5± 435.76

p=0.04
p=0.03
p=0.04

IgG3

Serum
BAL IgG3/urea
ELF

1119.21± 322.67
0.64±0.49
114.9±113.64

728.06± 289.53
1.01±0.84
167.02± 188.2

p=0.0007
p=0.05
p>0.05

IgG4

Serum
BAL IgG4/urea
ELF

405.79± 182.43
0.33±0.42
74.0± 133.9

284.41± 169.44
0.51±0.45
78.7± 77.9

p=0.02
p=0.05
p>0.05

(A)
P = 0.000 r=0.856
30
B
I
g 20
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G
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Figure 1.

P = 0.000 r=0.930
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Correlations between IgGsc levels to urea ratios in BAL and IgGsc levels in ELF.
a) Correlation between B-IgG1/urea and E-IgG1
b) Correlation between B-IgG2/urea and E-IgG2
c) Correlation between B-IgG3/urea and E-IgG3
d) Correlation between B-IgG4/urea and E-IgG4

(66%) had high values of at least one of the IgGscs, probably due to the frequent antigenic stimulation (25,29).

not establish any correlation between these parameters,
probably due to the clinical stability of our COPD subjects.

O’Keeffe and coworkers concluded that IgG2 in serum
and FEV1 were well correlated (2). However, we could

Smoking may increase some IgGsc levels in serum and
BAL fluid (30). This effect of smoking disappears in ex239
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smokers within a year. In Group I, the high levels of sIgGsc (IgG1,2,3,4) can not be explained by the effect of
smoking as both groups were all ex-smokers for at least
one year.
Alveolar surface epithelium and epithelial lining fluid
are rich in chemical substances and proteins. ELF obtained
by BAL can strongly represent the epithelial lining fluid.
The low level of a substance in ELF may account for an
impaired synthesis or transudation from the serum or an
increased local consumption of that substance (24,3032). IgG1 and IgG2 are synthesized in a negligible
amount in the lung tissue. However, IgG3 and IgG4 are
synthesized and expressed in the lung. Although serum
levels of IgG1 and IgG2 were elevated, E-IgGsc levels
were lower in Group I when compared to Group II. This
may be due to the disturbed transudation in lung tissue
or increased local consumption during lower respiratory
tract infections in patients with COPD. We were unable to
establish any correlation between the ELF and serum levels of IgGscs but B-IgGsc/urea ratios were strongly correlated with E-IgGsc representing BAL/urea correction as
accurate as ELF measurements (Figure 1).
The deficiency of IgA, IgG2 and IgG4 in sera may
cause chronic lung disease (13,15,29,33). We did not
detect any deficiency of one or more IgGsc in sera of the
subjects. However, we were unable to establish whether
this deficiency in ELF of COPD patients was the cause of
COPD or the result of acute exacerbations (Table 4).
The antibodies against several bacterial proteins are in
IgG1 nature (3,34). Infections with capsulated bacteria

like H. influenzae and S. pneumoniae, which usually cause
acute exacerbation in COPD, may occur frequently in the
IgG2 deficient patients (35). The local deficiency of IgG1
and IgG2 may be implicated for the local immunocompromisation that may be responsible for recurrent infections. This in turn can cause mucosal degeneration, which
can be visually evaluated through FOB by using CBI, which
was significantly higher in Group I.
In conclusion, deficiency in Igs and IgGscs has been
implicated for the pathogenesis of COPD. In these
patients, although the main class Ig levels are normal in
the serum, IgGsc levels can be high. Despite the normal
or high IgGsc levels in sera, there can be surprisingly
decreased levels of IgG1 and IgG2 in the lung tissue (in
ELF), probably due to deteriorated transudation or
increased utilisation in the alveolar spaces or airways.
This suggested an impaired local pulmonary immunological response in patients with COPD. Finally, we conclude
that deficiency of IgG1 and IgG2 in ELF may responsible
for the recurrent acute exacerbations in patients with
COPD but further studies need to be done in large series
about local humoral immunodeficiency in the lung.
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